Skip to main content
. 2021 Jun;9(12):1026. doi: 10.21037/atm-21-2298

Table 2. Published report as to the efficacy of preCRT.

Study Country Study design/study period No. of patients Outcome Complication
preCRT None- preCRT
Voogt (71) Netherlands Retrospective/2010–2018 132 NA pCR 17%
R0 63%
3-y OS 68%
3-y LRFS 72%
Major postoperative complications (Clavien-Dindo Grades III + IV + V) 31%
Ogawa (67) Japan Retrospective/2000–2014 25a 16a R0 93% vs. 94%
5-y OS 46.6% vs. 29.3% (P=0.12)
5-y LRFS 24.4% vs. 0% (P=0.02)
Major complications (Clavien-Dindo Grades III + IV), 28% vs. 43.8% (P=0.33)
Sorrentino (72) Italy Retrospective/2009–2017 49 103 R0 51% vs. 47.6% (P=0.691)
5-y DFS 60.4% vs. 33.6% (P=0.089)
5-y OS 84.6% vs. 71.1% (P=0.196)
Postoperative complications rates, 36.7% vs. 30.1% (P=0.413)
Bosman (63) Netherlands Retrospective/1994–2013 113b/135c 24 R0 62.8%/55.6% vs. 42%
5-y OS 39.1%/34.1% vs. 23%
(R0 + R1 + R2) (P=0.164)
5-y LRFS 59.7%/45.9% vs. 35% (P=0.003)
Major complications (Clavien-Dindo Grades III + IV + V), 39.7% vs. 34.8%
PelvEx Collaborative (73) International Retrospective/2004–2014 614 516 R0 59.9% vs. 56.4%5-y
OS 25.6% vs. 16.4% (R0 + R1 + R2) (P=0.008)
Major complication (Clavien-Dindo Grades III + IV) within 30 days, 61.3% vs. 38.7% (P<0.001)

a, patients with posterior invasive LRRC; b, the full-course group did not receive radiotherapy for the primary tumor, but received a full scheme of radiotherapy for recurrence; c, the reirradiation group received radiotherapy for the primary tumor and also for local recurrence. LRRC, locally recurrent rectal cancer; preCRT, preoperative chemoradiotherapy; pCR, pathological complete response; LRFS, local relapse-free survival; OS, overall survival; NA, not available.